Oramed Pharmaceuticals
ORMP
77 hedge funds and large institutions have $43.2M invested in Oramed Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 17 increasing their positions, 17 reducing their positions, and 12 closing their positions.
69% more capital invested
Capital invested by funds: $25.5M → $43.2M (+$17.7M)
67% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 12
44% more call options, than puts
Call options by funds: $5.34M | Put options by funds: $3.72M
8% more funds holding
Funds holding: 71 → 77 (+6)
0% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 17
0.94% less ownership
Funds ownership: 10.15% → 9.21% (-0.94%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LC
Lindbrook Capital
Calabasas,
California
|
+$2.98M |
| 2 |
JP Morgan Chase
New York
|
+$933K |
| 3 |
Jane Street
New York
|
+$707K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$489K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$444K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.64M |
| 2 |
Two Sigma Investments
New York
|
-$1.06M |
| 3 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$723K |
| 4 |
Two Sigma Advisers
New York
|
-$619K |
| 5 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$612K |
ORMP Hedge Fund Activity: Q4 2022 in Review
77 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q4 2022, worth a combined $43.2M — up 69% from $25.5M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ORMP positions and 12 closed out — a net gain of 8 holders — while 17 added to existing stakes and 17 trimmed.
The largest buyer was Lindbrook Capital, opening a new position worth an estimated $2.98M. The largest seller was Morgan Stanley, cutting an estimated $1.64M.
- 77 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q4 2022, up from 71 in Q3 2022.
- Funds reported $43.2M of Oramed Pharmaceuticals stock for Q4 2022, up 69% quarter-over-quarter.
- 20 funds opened new Oramed Pharmaceuticals positions in Q4 2022 and 12 closed out, a net change of +8 holders.
- The largest Oramed Pharmaceuticals buyer in Q4 2022 was Lindbrook Capital, an estimated $2.98M added.
- The largest Oramed Pharmaceuticals seller in Q4 2022 was Morgan Stanley, an estimated $1.64M sold.
Based on aggregated 13F filings for Q4 2022.